FDA names interim director to women's health post

Share this article:
The FDA named Theresa Toigo acting director of its Office of Women's Health (OWH).
She replaces Susan Wood, who quit this month in protest after the agency refused to permit OTC sales of Barr's Plan B emergency contraceptive -- a decision Wood said was politically-motivated.
Toigo is an FDA veteran who also heads the agency's Office of Special Health Issues.
 The FDA will conduct a search for a permanent replacement, an FDA spokeswoman told MM&M, although a timeframe for finding a permanent OWH director is not being given.
Lester Crawford, FDA commissioner, announced Toigo's appointment last Friday.
Crawford's own confirmation had been held up by Senate Democrats until the administration set a Sept. 1 deadline for FDA to make a decision on Plan B.
On Aug. 26, however, Crawford ordered a 60-day public comment period on Plan B, saying the regulatory and policy issues raised by Barr's application -- notably, whether Plan B can switch to OTC status for women ages 16 and older and remain prescription-only for those under 16 -- were too weighty to be decided behind closed doors.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.

Five things for Pharma Marketers to Know: Thursday, August 28

Five things for Pharma Marketers to Know: Thursday, ...

Human testing of GSK's Ebola virus starts next week, menopause is a costly healthcare concern, and a small conversation with pharmacists may have a big impact.